BR0014902A - Formulações orais para compostos antitumorais - Google Patents

Formulações orais para compostos antitumorais

Info

Publication number
BR0014902A
BR0014902A BR0014902-0A BR0014902A BR0014902A BR 0014902 A BR0014902 A BR 0014902A BR 0014902 A BR0014902 A BR 0014902A BR 0014902 A BR0014902 A BR 0014902A
Authority
BR
Brazil
Prior art keywords
oral formulations
antitumor compounds
pharmaceutically acceptable
stabilizing
compounds
Prior art date
Application number
BR0014902-0A
Other languages
English (en)
Inventor
Lorena Muggetti
Alessandro Martini
Paola Civaroli
Christopher James
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0014902A publication Critical patent/BR0014902A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçõES ORAIS PARA COMPOSTOS ANTITUMORAIS". A presente invenção é relacionada a um meio de preenchimento semi-sólido que compreende um derivado de camptotecina; uma matriz carreadora farmaceuticamente aceitável que é um glicerídeo poliglicolizado; e uma quantidade efetivamente redutora de espessamento e promotora de estabilização de um ou mais excipientes farmaceuticamente aceitáveis.
BR0014902-0A 1999-10-22 2000-10-02 Formulações orais para compostos antitumorais BR0014902A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925127.4A GB9925127D0 (en) 1999-10-22 1999-10-22 Oral formulations for anti-tumor compounds
PCT/EP2000/009647 WO2001030351A1 (en) 1999-10-22 2000-10-02 Oral formulations for anti-tumor compounds

Publications (1)

Publication Number Publication Date
BR0014902A true BR0014902A (pt) 2002-06-11

Family

ID=10863264

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014902-0A BR0014902A (pt) 1999-10-22 2000-10-02 Formulações orais para compostos antitumorais

Country Status (26)

Country Link
US (1) US7201913B1 (pt)
EP (1) EP1223936A1 (pt)
JP (1) JP2003512430A (pt)
KR (1) KR100838097B1 (pt)
CN (1) CN1198616C (pt)
AR (1) AR031834A1 (pt)
AU (1) AU784201B2 (pt)
BR (1) BR0014902A (pt)
CA (1) CA2387648A1 (pt)
CO (1) CO5251471A1 (pt)
CZ (1) CZ20021372A3 (pt)
EA (1) EA008284B1 (pt)
GB (1) GB9925127D0 (pt)
HK (1) HK1048253B (pt)
HU (1) HUP0202850A3 (pt)
IL (2) IL149044A0 (pt)
MX (1) MXPA02003904A (pt)
MY (1) MY138106A (pt)
NO (1) NO322782B1 (pt)
NZ (1) NZ518398A (pt)
PE (1) PE20010809A1 (pt)
PL (1) PL356236A1 (pt)
SK (1) SK5102002A3 (pt)
TW (1) TWI233355B (pt)
WO (1) WO2001030351A1 (pt)
ZA (1) ZA200203042B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE344670T1 (de) * 2000-02-28 2006-11-15 Pfizer Entpr Sarl Synergistische kombination zur behandlung von kolorektalkarzinom
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
ITRM20030074A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
US20070053869A1 (en) * 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
JP5297815B2 (ja) * 2007-01-26 2013-09-25 株式会社ポーラファルマ 医薬組成物
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
CN101998851A (zh) * 2008-02-08 2011-03-30 帕纳德制药公司 吡铂和西妥昔单抗治疗结直肠癌的用途
HUP0900614A2 (en) * 2009-09-29 2011-05-30 Mate Dr Hidvegi Preparation comprising dehydrated, fermented material with amorphous crystaline structure and process for its production
JP2013512948A (ja) * 2009-12-08 2013-04-18 イル・ファ・カンパニー・リミテッド ２０−Ｏ−β−Ｄ−グルコピラノシル−２０（Ｓ）−プロトパナキサジオールを含む固体分散体
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CN110946836A (zh) * 2014-01-17 2020-04-03 昂科拉制药有限公司 用于治疗癌症的伊立替康的固体口服剂型
CN104524588A (zh) * 2014-12-05 2015-04-22 天津键凯科技有限公司 一种聚乙二醇修饰的喜树碱类衍生物的药物组合物及其制备方法
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
KR102185475B1 (ko) 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236393A (en) * 1989-12-13 1992-05-26 Lilly Co Eli N-alkylated glycopeptide derivatives prepared from antibiotics a82846 series and pa-42867-a; pharmaceutical compositions
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5433951A (en) 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
IL115099A (en) * 1994-10-14 1999-04-11 Upjohn Co Lyophilizate of phospholipid complex of water insoluble camptothecins
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5954998A (en) * 1995-05-25 1999-09-21 The Clorox Company Liquid peracid precursor colloidal dispersions: oil-core vesicles
ATE554750T1 (de) * 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
GB9711962D0 (en) * 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
JP5005847B2 (ja) * 1997-07-29 2012-08-22 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 親油性化合物用の自己乳化性処方
AR013261A1 (es) * 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
CA2373931A1 (en) * 1999-05-17 2000-11-23 Richard Love Dfmo and celecoxib in combination for cancer chemoprevention and therapy
GB9918885D0 (en) * 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules

Also Published As

Publication number Publication date
IL149044A0 (en) 2002-11-10
MY138106A (en) 2009-04-30
AU784201B2 (en) 2006-02-23
KR20020045613A (ko) 2002-06-19
KR100838097B1 (ko) 2008-06-13
AU7661300A (en) 2001-05-08
CA2387648A1 (en) 2001-05-03
EP1223936A1 (en) 2002-07-24
MXPA02003904A (es) 2003-07-14
NZ518398A (en) 2004-01-30
TWI233355B (en) 2005-06-01
HUP0202850A3 (en) 2004-12-28
EA200200480A1 (ru) 2002-10-31
HK1048253B (zh) 2005-12-02
US7201913B1 (en) 2007-04-10
EA008284B1 (ru) 2007-04-27
HUP0202850A2 (hu) 2003-01-28
CZ20021372A3 (cs) 2002-09-11
GB9925127D0 (en) 1999-12-22
HK1048253A1 (en) 2003-03-28
NO322782B1 (no) 2006-12-11
NO20021834L (no) 2002-04-18
PE20010809A1 (es) 2001-08-01
CO5251471A1 (es) 2003-02-28
WO2001030351A1 (en) 2001-05-03
PL356236A1 (en) 2004-06-28
JP2003512430A (ja) 2003-04-02
IL149044A (en) 2007-03-08
CN1382050A (zh) 2002-11-27
NO20021834D0 (no) 2002-04-18
SK5102002A3 (en) 2002-11-06
AR031834A1 (es) 2003-10-08
CN1198616C (zh) 2005-04-27
ZA200203042B (en) 2003-04-17

Similar Documents

Publication Publication Date Title
BR0014902A (pt) Formulações orais para compostos antitumorais
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
BR0008059A (pt) Composições de valdecoxib
EP1033981A4 (en) FORMULATIONS AND METHODS FOR REDUCING THE TOXICITY OF ANTINEOPLASTIC AGENTS
NZ514574A (en) Novel method of treatment
LU91854I2 (fr) Eribulin et ses dérivés pharmaceutiquement acceptables (HALAVEN®)
HK1076605A1 (en) Formulations
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
PL342988A1 (en) Novel galenic formulations of meloxicam for oral administration
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
UY27969A1 (es) Formulaciones que comprenden un compuesto de indolinona
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
HUP0302635A2 (hu) Valpronsav foszfolipidszármazékai és ezek keveréke
HUP0003546A3 (en) Compositions for administering taxanes orally to human patients
HUP0401042A2 (hu) Primer álmatlanság kezelésére alkalmas gyógyszerkészítmények
IL125628A0 (en) Benzo[c] quinolizine derivatives their preparation and use as 5alpha-reductase inhibitors
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
PT1206248E (pt) Composicoes sedativo-hipnoticas de libertacao controlada e metodos relacionados com os mesmos
DE69532819D1 (de) Kohlenhydrate derivate und die enthaltende zusammensetzungen
BR0014687A (pt) Compostos de taxano pentacìclico
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina
IL111138A (en) Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT: A61K 31/47, A61K 9/48, A61P 35/00

Ipc: A61K 31/47 (2009.01), A61K 9/48 (2009.01)

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements